|
WO2019241536A1
|
|
Oxabicycloheptanes for enhancing car t cell function
|
|
WO2019113155A1
|
|
Oxabicycloheptanes for treatment of secondary acute myeloid leukemia
|
|
KR20190098995A
|
|
Oxabicycloheptane for the regulation of immune responses
|
|
CN109475543A
|
|
With the clinical protocol of inhibitors of phosphatases treatment myelodysplastic syndromes
|
|
AU2016263079A1
|
|
Oxabicycloheptane prodrugs
|
|
AU2016219853A1
|
|
Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
|
|
US2017305925A1
|
|
Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid
|
|
CA2960989A1
|
|
Human dosing of phosphatase inhibitor
|
|
KR20160004299A
|
|
Formulations of oxabicycloheptanes and oxabicycloheptenes
|
|
IL229476D0
|
|
Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
|
|
CA2877167A1
|
|
Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
|
|
CN104619710A
|
|
Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury
|
|
CA2836940A1
|
|
Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
|
|
WO2010147612A1
|
|
Methods of modulating cell regulation by inhibiting p53
|
|
CA2730148A1
|
|
Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
|
|
AU2009277179A1
|
|
Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
|
|
CA2700857A1
|
|
Hdac inhibitors
|
|
WO2009020565A1
|
|
Use of phosphatases to treat neuroblastomas and medulloblastomas
|
|
US2009036309A1
|
|
Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use
|
